The sPLA2 inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown.OBJECTIVE: To determine the effects of sPLA2 inhibition with varespladib on cardiovascular outcomes.